Mumps virus vaccine live
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Mumps virus vaccine live
- mumpsvax
- Mumpsvax
- mumps live attenuated
- mumps vaccine
- Mumps vaccine
- Mumps vaccine (live attenuated)
- mumps vaccine live attenuated
- mumps virus live antigen a
- Mumps virus live antigen, a
- mumps virus vaccine live
- Mumps virus vaccine live
- Mumps virus vaccine,live
- Mumps, live attenuated
- Virus mumps (jeryl lynn strain)
- virus mumps jeryl lynn strain
- ATC classification codes
- J07BE01
Sources for recorded values
- ChEMBL ID
- CHEMBL2109201
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Meningococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004249
- Subject identifier
- D008589
- Condition
- Rubulavirus Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007383
- Subject identifier
- D019351
- Condition
- Measles
- Highest recorded phase
- 2
- Condition identifier
- EFO:1002025
- Subject identifier
- D008457
- Condition identifier
- EFO_0007383
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004619
- Highest recorded phase
- 4
- Event
- disseminated varicella zoster vaccine virus infection
- Reports
- 1
- Reporting signal score
- 9.36828
- Event
- haemoglobin s
- Reports
- 1
- Reporting signal score
- 12.7355
- Event
- rubella
- Reports
- 1
- Reporting signal score
- 8.99792
- NCT00109278
- NCT01712906
- NCT04591405
- NCT05065177
- NCT03630705
- NCT03691610
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (67)
- A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
- A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children
- A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
- A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
- A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults
- A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine
- A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults
- A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
- A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers
- A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
- An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine
- Analysis on AEFI Surveillance Data for Live Attenuated Varicella Vaccine
- Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India
- Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants
- Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
- Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan
- Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
- Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults
In development for (3)
- Measles Phase 2
- Meningococcal infection Phase 3
- Mumps infectious disease Phase 3